These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38021444)

  • 41. WZ4003 sensitizes non-small cell lung cancer cells to gefitinib via inhibition of ARK5 and epithelial-to-mesenchymal transition.
    Chen J; Zhang S; Zheng X; Mao J; Xie S; Chen W; Ran X
    Am J Transl Res; 2020; 12(11):7377-7385. PubMed ID: 33312374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer.
    Chen J; Shi L; Qian Y; Jin Y; Dong N; Chen C; Wang B
    J Thorac Dis; 2023 Jun; 15(6):3359-3371. PubMed ID: 37426126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK; Biswal BK
    Life Sci; 2021 Jul; 277():119608. PubMed ID: 33989664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Wang Q; Li X; Ren S; Su C; Li C; Li W; Yu J; Cheng N; Zhou C
    Lung Cancer; 2020 Sep; 147():99-105. PubMed ID: 32683208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extracellular heat shock protein 90α mediates HDM-induced bronchial epithelial barrier dysfunction by activating RhoA/MLC signaling.
    Dong HM; Le YQ; Wang YH; Zhao HJ; Huang CW; Hu YH; Luo LS; Wan X; Wei YL; Chu ZQ; Li W; Cai SX
    Respir Res; 2017 May; 18(1):111. PubMed ID: 28558721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiR-598 Suppresses Invasion and Migration by Negative Regulation of Derlin-1 and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.
    Yang F; Wei K; Qin Z; Liu W; Shao C; Wang C; Ma L; Xie M; Shu Y; Shen H
    Cell Physiol Biochem; 2018; 47(1):245-256. PubMed ID: 29768262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.
    Li L; Gu X; Yue J; Zhao Q; Lv D; Chen H; Xu L
    Oncotarget; 2017 Nov; 8(54):92240-92253. PubMed ID: 29190911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
    Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):947-54. PubMed ID: 24606853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells.
    Jeong J; Kim J
    Front Pharmacol; 2021; 12():639095. PubMed ID: 33967774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition.
    Duan Q; Pang C; Chang N; Zhang J; Liu W
    Oncol Rep; 2016 Jul; 36(1):551-8. PubMed ID: 27176594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
    Wang W; Xia X; Chen K; Chen M; Meng Y; Lv D; Yang H
    Front Oncol; 2021; 11():665045. PubMed ID: 34168988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.
    Lu X; Zhang Y; Pan Y; Cao M; Zhou X; Zhang T
    Oncol Lett; 2021 Jan; 21(1):40. PubMed ID: 33262832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: Implication in epithelial-mesenchymal transition and gefitinib resistance.
    Ibrahim FM; Helal DS; Ali DA; Abd-Ellatif RN; Elkady AM; Sharshar R; Gharib F; Abo Elnasr M; El-Guindy DM
    Pathol Res Pract; 2023 Jan; 241():154293. PubMed ID: 36586309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
    Chung JH; Rho JK; Xu X; Lee JS; Yoon HI; Lee CT; Choi YJ; Kim HR; Kim CH; Lee JC
    Lung Cancer; 2011 Aug; 73(2):176-82. PubMed ID: 21168239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1.
    Tian Y; Wang C; Chen S; Liu J; Fu Y; Luo Y
    J Cell Sci; 2019 Jul; 132(15):. PubMed ID: 31273033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
    Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
    J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
    Ju L; Zhou C
    Cancer Biomark; 2013; 13(5):329-36. PubMed ID: 24440972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.